Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...
Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...
The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback